The characteristics of Grave’s disease in children and adolescent patients in Al-Madinah Al-Munawwarah

References

1. 1.↵
   1. Alenazi B,
   2. Alanazi A,
   3. Alshaya A,
   4. Al Duraibi S,
   5. Mousa A,
   6. Aseifan T, et al.

   Pediatric Graves’ disease: a case report. IJHSR 2017; 7: 4.

   OpenUrl
2. 2.↵
   1. Marques O,
   2. Antunes A,
   3. Oliveira MJ.

   Treatment of Graves’ disease in children: the Portuguese experience. Endocrinol Diabetes Nutr (Engl Ed) 2018; 65: 143–149. Spanish

   OpenUrl
3. 3.↵
   1. Smith TJ,
   2. Hegedüs L.

   Graves’ disease. N Engl J Med 2016; 375: 1552–1565.

   OpenUrlPubMed
4. 4.↵
   1. Kliegman RM,
   2. Stanton BF,
   3. Geme JS,
   4. Schor NF

   , editors. Nelson Textbook of Pediatrics, 2-Volume. 20th edition. Philadelphia (PA): Elsevier; 2015. Available from: https://archive.org/details/NelsonTextbookOfPediatrics20E2/page/n10/mode/1up
5. 5.↵
   1. Okawa ER,
   2. Grant FD,
   3. Smith JR.

   Pediatric Graves’ disease: decisions regarding therapy. Curr Opin Pediatr 2015; 27: 442–447.

   OpenUrl
6. 6.↵
   1. Minamitani K,
   2. Sato H,
   3. Ohye H,
   4. Harada S,
   5. Arisaka O.

   Guidelines for the treatment of childhood-onset Graves’ disease in Japan, 2016. Clin Pediatr Endocrinol 2017; 26: 29–62.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Metwalley KA,
   2. Farghaly HS,
   3. Abdelhamid A.

   Left ventricular functions in children with newly diagnosed Graves’ disease. A single-center study from Upper Egypt. Eur J Pediatr 2018; 177: 101–106.

   OpenUrl
8. 8.↵
   1. Mirghani H,
   2. Alsalem SSS,
   3. Aljuhani SSH,
   4. Alharbi ANJ,
   5. Alsaiari ASM,
   6. Almutairi DSL.

   Thyroid status among children with psychiatric disease in Tabuk City, the Kingdom of Saudi Arabia. Medical Science 2021; 25: 1758–1764. https://www.researchgate.net/publication/353347901_Thyroid_status_among_children_with_psychiatric_disease_in_Tabuk_City_the_Kingdom_of_Saudi_Arabia

   OpenUrl
9. 9.↵
   1. Rivkees SA.

   Controversies in the management of Graves’ disease in children. J Endocrinol Invest 2016; 39: 1247–1257.

   OpenUrl
10. 10.↵
    1. Malabu UH,
    2. Alfadda A,
    3. Sulimani RA,
    4. Al-Rubeaan KA,
    5. Al-Ruhaily AD,
    6. Fouda MA, et al.

    Graves’ disease in Saudi Arabia: a 10-year hospital study. J Pak Med Assoc 2008; 58: 302–304.

    OpenUrlPubMed
11. 11.↵
    [Bansal S, Umpaichitra V, Desai N, Pérez S, Perez-Colon S. Pediatric Graves’ disease. International Journal of Endocrinology and Metabolic Disorders 2015; 1: 1–6.

    OpenUrl
12. 12.↵
    1. Schneider Aguirre R,
    2. Khalid A,
    3. Ismail HM,
    4. Nabhan Z.

    Methimazole desensitization in a 4-year-old with refractory Graves disease. AACE Clin Case Rep 2021; 7: 273–276.

    OpenUrl
13. 13.↵
    1. Chen M,
    2. Lash M,
    3. Nebesio T,
    4. Eugster E.

    Change in BMI after radioactive iodine ablation for graves disease. Int J Pediatr Endocrinol 2017; 2017: 5.

    OpenUrl
14. 14.↵
    1. Fanning E,
    2. Inder WJ,
    3. Mackenzie E.

    Radioiodine treatment for graves’ disease: a 10-year Australian cohort study. BMC Endocr Disord 2018; 18: 94.

    OpenUrl
15. 15.
    1. Pratita W,
    2. Arto K,
    3. Arto K.

    Efficacy of vitamin-D supplement on thyroid profile in children with Graves’ disease. Open Access Macedonian Journal of Medical Sciences 2020; 8: 798–801.

    OpenUrl
16. 16.
    1. Thewjitcharoen Y,
    2. Karndumri K,
    3. Chatchomchuan W,
    4. Porramatikul S,
    5. Krittiyawong S,
    6. Wanathayanoroj E, et al.

    Practice patterns and outcomes in the management of Thai patients with Graves’ disease. Thyroid Res 2021; 14: 5.

    OpenUrl
17. 17.↵
    1. Sadeghi Y,
    2. Obéric A,
    3. Theintz G,
    4. Hamédani M.

    Graves’ ophthalmopathy in a paediatric population. Klin Monbl Augenheilkd 2017; 234: 591–594.

    OpenUrl
18. 18.↵
    1. Azagoh-Kouadio R,
    2. Asse KV,
    3. Enoh JS,
    4. Couitchere LG,
    5. Yao KC,
    6. Cisse L, et al.

    Hyperthyroidism of the child in Abidjan (Côte d’Ivoire). Retrospective study of 27 cases. International Journal of Pediatrics and Neonatal Health 2018; 2: 38–42.

    OpenUrl
19. 19.
    1. Puthenpura V,
    2. Desai K,
    3. Bauer A,
    4. Marshall I.

    Delayed methimazole-induced agranulocytosis in a 6-year old patient with Graves’ disease. Int J Pediatr Endocrinol 2016; 2016: 16.

    OpenUrl
20. 20.
    1. Han TY,
    2. Lee JH,
    3. Noh TK,
    4. Choi MW,
    5. Yun JS,
    6. Lee KH, et al.

    Alopecia areata and overt thyroid diseases: a nationwide population-based study. J Dermatol 2018; 45: 1411–1417.

    OpenUrl
21. 21.↵
    1. Léger J,
    2. Oliver I,
    3. Rodrigue D,
    4. Lambert AS,
    5. Coutant R.

    Graves’ disease in children. Ann Endocrinol (Paris) 2018; 79: 647–655.

    OpenUrlPubMed
22. 22.↵
    1. Bojic T,
    2. Paunovic I,
    3. Diklic A,
    4. Zivaljevic V,
    5. Zoric G,
    6. Kalezic N, et al.

    Total thyroidectomy as a method of choice in the treatment of Graves’ disease - analysis of 1432 patients. BMC Surg 2015; 15: 39.

    OpenUrl
23. 23.↵
    1. Ross DS,
    2. Burch HB,
    3. Cooper DS,
    4. Greenlee MC,
    5. Laurberg P,
    6. Maia AL, et al.

    2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26: 1343–1421.

    OpenUrlCrossRefPubMed